CeloNova BioSciences Release: First-In-Man Study Of The COBRA PzF Coronary Stent Shows Promising Results Highlighted By Short, 30-Day Dual-Antiplatelet Therapy And Low, 3% TLR Rate
WASHINGTON--(BUSINESS WIRE)--CeloNova BioSciences, Inc., today announced that positive First-in-Man (FIM) clinical trial results found its COBRA PzF™ coronary stent system with an advanced nano-thin coating of Polyzene®-F polymer to be a safe and effective routine interventional treatment for real-world and complex patients with heart disease.
Help employers find you! Check out all the jobs and post your resume.